Description

Erectile dysfunction (ED) affects millions of men in the United States and globally. While several FDA-approved oral medications are available to support erectile function, many patients report challenges with onset timing, duration windows, food interactions, and psychological arousal factors.

MEDVi’s QUAD® is a clinician-prescribed, compounded medication that combines four active pharmaceutical ingredients into a single sublingual formulation. The goal: address multiple physiological pathways involved in sexual performance within one integrated treatment plan.

This article provides a detailed overview of QUAD® by MEDVi, including:

• What QUAD® is
• How each ingredient works
• The rationale behind combining four agents
• Sublingual absorption vs. traditional oral tablets
• Safety considerations
• The telehealth prescribing model
• Frequently asked clinical questions

Understanding Erectile Dysfunction: A Multifactorial Condition

Erectile dysfunction is rarely caused by a single issue. In most cases, it involves a combination of:

• Vascular factors (reduced blood flow)
• Neurological signaling
• Hormonal influences
• Psychological components (stress, anxiety, performance pressure)
• Medication side effects
• Metabolic conditions such as diabetes or cardiovascular disease

Traditional ED medications typically target one pathway: increasing blood flow to penile tissue by inhibiting phosphodiesterase type 5 (PDE5). While effective for many patients, some men report that single-agent therapy does not fully address timing concerns or psychological desire components.

This multifactorial reality is the foundation for QUAD®’s multi-mechanism design.

What Is QUAD® by MEDVi?

QUAD® is a compounded prescription medication that combines:

1. Apomorphine
2. Vardenafil
3. Sildenafil
4. Tadalafil

It is formulated as a rapid-absorb sublingual liquid, designed to dissolve under the tongue rather than be swallowed as a traditional tablet.

According to MEDVi, the treatment is:

• Prescribed by a US-licensed clinician
• Compounded by partnered US pharmacies
• Delivered discreetly
• Available after a telehealth evaluation

Important: QUAD® is a compounded medication. Compounded medications are not individually FDA-approved as finished products, though they may contain FDA-approved active ingredients. They are prepared by licensed pharmacies pursuant to a prescription.

Ingredient Breakdown: Mechanisms and Clinical Rationale

1. Apomorphine – Central Dopamine Activation

Class: Dopamine receptor agonist
Primary Action: Central nervous system signaling

Apomorphine works differently from PDE5 inhibitors. Rather than acting primarily on blood vessels, it targets dopamine receptors in the brain.

Dopamine plays a role in:

• Sexual desire
• Arousal signaling
• Motivation pathways

By activating dopamine receptors, apomorphine may help bridge the gap between psychological arousal and physical response. This mechanism is particularly relevant for men whose ED involves a strong psychological or desire component.

Unlike PDE5 inhibitors, apomorphine acts centrally rather than peripherally.

---

2. Vardenafil – Rapid Onset PDE5 Inhibitor

Class: PDE5 inhibitor
Primary Action: Enhances nitric oxide–mediated blood flow
Typical Onset: Often faster than some alternatives

Vardenafil works by inhibiting PDE5, the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP). cGMP relaxes smooth muscle in penile tissue, allowing increased blood flow.

Clinical characteristics commonly associated with vardenafil:

• Relatively rapid onset
• Potent PDE5 inhibition
• Shorter duration compared to tadalafil

In QUAD®, vardenafil may contribute to earlier responsiveness after dosing.

3. Sildenafil – Established PDE5 Therapy

Class: PDE5 inhibitor
Primary Action: Enhances erectile blood flow
Duration: Intermediate

Sildenafil was the first widely adopted PDE5 inhibitor for ED treatment. It remains one of the most studied erectile dysfunction medications.

Its clinical profile typically includes:

• Reliable erectile support
• Onset within approximately 30–60 minutes (when swallowed)
• Duration of several hours

In combination therapy, sildenafil may contribute to peak rigidity and vascular support.

4. Tadalafil – Extended Duration PDE5 Inhibitor

Class: PDE5 inhibitor
Primary Action: Prolonged PDE5 inhibition
Duration: Up to 36 hours in some patients

Tadalafil has a longer half-life compared to sildenafil and vardenafil. It is often referred to as a “weekend” medication because its effects may persist for up to 36 hours.

In QUAD®, tadalafil may:

• Extend the response window
• Reduce timing anxiety
• Support spontaneity over a longer duration

Importantly, prolonged activity does not mean continuous erection. PDE5 inhibitors facilitate erection in response to stimulation; they do not cause involuntary, continuous erections under normal use.

Why Combine Multiple PDE5 Inhibitors?

This is a key clinical question.

In traditional practice, patients typically use one PDE5 inhibitor at a time. However, compounded regimens sometimes combine agents with differing pharmacokinetics.

Potential theoretical advantages of combining agents:

• Faster onset from one agent
• Greater peak intensity from another
• Longer duration from a third

However, combining multiple PDE5 inhibitors also increases the need for:

• Careful dose control
• Cardiovascular risk screening
• Drug interaction evaluation

That is why telehealth screening and clinician oversight are critical.

Sublingual Delivery: How It Differs from Swallowed Tablets

QUAD® is designed to dissolve under the tongue.

Why Sublingual?

The sublingual area contains a rich network of blood vessels. Medications absorbed here may enter systemic circulation more directly.

Potential advantages of sublingual absorption:

• Avoids full first-pass metabolism in the liver
• May result in faster systemic availability
• May reduce food-related absorption variability

Traditional oral PDE5 tablets must:

1. Pass through the stomach
2. Be absorbed in the small intestine
3. Undergo hepatic metabolism

High-fat meals can delay absorption of some PDE5 inhibitors when taken orally.

Sublingual delivery aims to reduce this variability, though individual response still varies.

Onset and Duration: What Patients Should Realistically Expect

Marketing language often emphasizes rapid activation and long duration. From a clinical standpoint:

• Onset can vary based on metabolism, cardiovascular status, and concurrent medications.
• Psychological factors significantly influence outcomes.
• Not every patient will experience identical response timing.

Typical characteristics associated with the individual ingredients:

• Vardenafil: Often faster onset relative to some alternatives
• Sildenafil: Reliable short-term support
• Tadalafil: Longer duration window
• Apomorphine: Central arousal signaling support

Patients should view the formulation as a multi-mechanism approach rather than a guarantee of performance.

Safety Considerations

Because QUAD® contains multiple active agents, safety screening is essential.

Who Should Not Use PDE5 Inhibitors?

Patients taking:

• Nitrates (e.g., nitroglycerin)
• Certain alpha blockers
• Guanylate cyclase stimulators

These combinations may cause dangerous drops in blood pressure.

Cardiovascular Evaluation

Men with:

• Recent heart attack
• Unstable angina
• Severe heart failure
• Uncontrolled hypertension

Should undergo medical evaluation before any ED medication.

Common Side Effects of PDE5 Inhibitors

• Headache
• Flushing
• Nasal congestion
• Indigestion
• Visual changes (rare but documented)

Apomorphine Considerations

Apomorphine may cause:

• Nausea
• Dizziness
• Hypotension
• Rare fainting

Because QUAD® combines agents, dose calibration is essential to minimize cumulative side effects.

Telehealth Model: How MEDVi Prescribing Works

According to MEDVi’s model:

Step 1: Online Evaluation

Patients complete a secure intake form, typically taking a few minutes.

Step 2: Physician Review

A US-licensed clinician reviews:

• Medical history
• Medication list
• Cardiovascular risk
• Contraindications

If appropriate, a prescription is issued.

Step 3: Compounding and Delivery

Partnered pharmacies prepare the medication and ship it discreetly.

Patients reportedly receive:

• Doctor consultation
• Shipping included
• Ongoing medical support

Compounded Medications: What Patients Should Know

Compounded medications:

• Are prepared by licensed pharmacies
• Are customized based on a prescription
• Are not mass-manufactured FDA-approved finished products

Active ingredients may be FDA-approved individually, but the compounded combination is not separately approved as a single commercial drug.

Patients should discuss:

• Risks and benefits
• Off-label considerations
• Individual suitability

Comparing QUAD® to Single-Agent Therapy

Traditional ED platforms often prescribe:

• Sildenafil alone
• Tadalafil alone
• Vardenafil alone

A compounded multi-agent approach may appeal to patients who:

• Did not achieve satisfactory results from single agents
• Want broader coverage of onset and duration
• Experience significant timing anxiety

However, combination therapy may not be necessary for all patients. Individualized care remains the standard.

Addressing Common Questions

Will this cause a 36-hour continuous erection?

No. PDE5 inhibitors enhance the natural erectile response to sexual stimulation. They do not create involuntary erections under normal use.

If an erection lasts longer than 4 hours (priapism), immediate medical care is required.

Is combining ingredients safe?

Safety depends on:

• Proper dosing
• Medical screening
• Individual cardiovascular status
• Avoiding contraindicated medications

Compounded therapy should only be used under licensed medical supervision.

Does sublingual mean it works instantly?

Not instantly. Sublingual absorption may shorten onset time in some patients, but response varies.

Psychological Impact: Reducing Timing Anxiety

Many men report that the unpredictability of ED medications contributes to stress.

A longer response window (as associated with tadalafil) may:

• Reduce pressure to time intimacy
• Improve confidence
• Support relationship satisfaction

Addressing psychological components is often as important as pharmacological support.

Cost and Value Considerations

MEDVi positions QUAD® as a bundled approach compared to purchasing separate prescriptions.

Patients should evaluate:

• Monthly pricing
• Clinical need for multi-agent therapy
• Insurance coverage
• Telehealth convenience

ED treatment costs vary widely depending on pharmacy, dosage, and insurance.

Who May Be a Candidate?

Men who:

• Have ED confirmed by a clinician
• Have tried single agents without optimal results
• Desire broader onset + duration coverage
• Are medically cleared for PDE5 therapy

Not appropriate for:

• Patients on nitrates
• Severe cardiovascular instability
• Certain retinal disorders
• Known hypersensitivity to components

The Role of Medical Supervision

ED can be an early sign of:

• Cardiovascular disease
• Diabetes
• Metabolic syndrome
• Hormonal imbalance

Treatment should not replace comprehensive health evaluation.

Regular follow-ups are important for:

• Monitoring side effects
• Adjusting dosage
• Screening cardiovascular risk

Final Thoughts: Is QUAD® Right for You?

QUAD® by MEDVi represents a compounded, multi-mechanism approach to erectile dysfunction treatment. By combining apomorphine with three PDE5 inhibitors in a sublingual formulation, it aims to address:

• Desire signaling
• Rapid onset
• Peak erectile strength
• Extended duration

However, combination therapy increases the importance of:

• Physician oversight
• Cardiovascular screening
• Medication interaction review

Erectile dysfunction is highly individualized. What works for one patient may not work for another.

If considering compounded ED therapy:

• Discuss full medical history with a licensed provider
• Understand potential risks
• Set realistic expectations

Effective ED management balances pharmacology, cardiovascular health, psychological well-being, and open communication.